DBV Technologies Update
Montrouge, France, March 13, 2023
DBV Technologies Update
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), a clinical-stage biopharmaceutical company, informs its investors that it does not hold cash deposits or securities at Silicon Valley Bank.
About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food-allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
Forward Looking Statements
This press release may contain forward-looking statements and estimates, including statements regarding the therapeutic potential of Viaskin™ Peanut as a treatment for peanut-allergic children and the potential benefits of EPIT™, DBV Technologies’ clinical development and regulatory plans, timing and projections of VITESSE study milestones, and timing and anticipated results of interactions with regulatory agencies. All statements about VITESSE study milestones, enrollment and anticipated results contained herein are DBV’s best estimates and projections are based on performance of previous studies and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements with respect to the VITESSE study to differ materially from the estimates and projections contained herein. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties and may be impacted by market conditions as well as other risks and uncertainties set forth in DBV Technologies’ regulatory filings with the Autorité des Marchés Financiers (“AMF”), DBV Technologies’ filings and reports with the U.S. Securities and Exchange Commission (“SEC”) and future filings and reports made with the AMF and SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.
Viaskin and EPIT are trademarks of DBV Technologies.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Ny afdeling Balance C Akkumulerende i Investeringsforeningen PFA Invest31.3.2023 11:27:08 CEST | Press release
Investeringsforeningen PFA Invests bestyrelse har den 8. marts 2023 besluttet at oprette af en ny afdeling, Balance C Akkumulerende. Afdelingen blev godkendt af Finanstilsynet den 10. januar 2023. Vedlagt offentliggøres tegningsprospektet for afdelingen under Investeringsforeningen PFA Invest • Balance C Akkumulerende Andele i afdelingen udbydes til tegning fra den 11. april 2023 til den 24. april 2023, begge dage inklusive, og andele udbydes i tegningsperioden til tegningskurs 100,20. Tegning af min. 1 mio. kr. i afdelingen er garanteret af PFA Pension, forsikringsaktieselskab. Resultat af tegningen forventes offentliggjort den 25. april 2023. NASDAQ OMX Copenhagen A/S har godkendt at andelene optages til handel med forventet 1. handelsdag den 28. april 2023. Yderligere information kan findes på www.pfainvest.dk Med venlig hilsen PFA Asset Management A/S Attachment Tegningsprospekt PFA Invest - Balance C Akkumulerende
Indkaldelse til ordinær generalforsamling i EAC Invest A/S - Selskabsmeddelelse nr. 2/202331.3.2023 10:58:37 CEST | pressemeddelelse
København, 31. marts 2023 Den ordinære generalforsamling i EAC Invest A/S vil blive afholdt fredag den 28. april 2023 kl. 11:00 i Asia House, Indiakaj 16, 2100 København Ø. Vedhæftet dagsorden med bilag. Med venlig hilsen, for EAC Invest A/S Bestyrelsen For yderligere information Kresten M. Valdal, CEO,Telefon: +45 82334044, e-mail firstname.lastname@example.org Vedhæftede filer EAC Invest AS - AGM 2023 IndkaldelseEAC Invest AS - AGM 2023 - Bilag 1 - Bestyrelseskandidater2023.02 Indkaldelse til ordinær generalforsamling i EAC Invest AS
Decisions of Innofactor Plc’s Annual General Meeting and the organizing meeting of the Board of Directors31.3.2023 10:20:00 CEST | Press release
Innofactor Plc Stock Exchange Release March 31, 2023, at 11.20 Finnish time Adopting the accounts and the group's financial statement and granting the members of the Board of Directors and the Chief Executive Officer discharge from liability The Annual General Meeting (AGM) of Innofactor Plc held on March 31, 2023, resolved to adopt the accounts and the group's financial statement for the financial period that ended on December 31, 2022, and granted the members of the Board of Directors and the Chief Executive Officer discharge from liability for the financial period that ended on December 31, 2022. Deciding on the use of the profit shown on the balance sheet and the payment of dividend The AGM decided, in accordance with the proposal of the Board of Directors, that no dividend will be paid for the financial period of 2022. The AGM decided on a repayment of capital of EUR 0,06 per share to be paid. The repayment of capital shall be paid to shareholders who on the record date of the cap
AFARAK GROUP SE'S PUBLISHES FINANCIAL STATEMENTS 202231.3.2023 10:18:29 CEST | Press release
09:15 London, 11:15 Helsinki, 31 March 2023 - Afarak Group SE ("Afarak" or "the Company") (LSE: AFRK, OMX: AFAGR) Annual Financial Report AFARAK GROUP SE'S PUBLISHES FINANCIAL STATEMENTS 2022 Afarak Group announces that it has published today its Board of directors report, Financial Statement for the year 2022, the Auditor’s Report and the Corporate Governance Statement which is available from the Company's website www.afarak.com. Afarak publishes the Financial Statements in accordance with European Single Electronic Format (ESEF) reporting requirements with the XHTML format labelled with XBRL tags, which are available as zip file attached to this release. A copy of the Board of Directors report and the Financial Statements for the year 2022 has been submitted to the UK's National Storage Mechanism. Afarak will hold its 2023 Annual General Meeting in Helsinki on within the time stipulated in the Finnish Companies Act. Helsinki 31 March 2023 Guy Konsbruck CEO For additional information,
Agillic named a leader in The Cross-Channel Marketing Hubs Landscape, Q1 2023 report by Independent Research Firm31.3.2023 10:02:56 CEST | Press release
Press release, Copenhagen, 31 March 2023 Agillic’s Omnichannel Marketing Automation Platform has been named in Forrester’s ‘The Cross-Channel Marketing Hubs Landscape, Q1 2023’ report as a notable vendor among CCMH vendor options for B2C marketing. The Forrester report for Cross-Channel Marketing Hubs (CCMHs) allows B2C executives to understand the value they can expect from a CCMH vendor, learn how vendors differ, and select the right one based on size and market focus. In the report, Forrester defines CCMHs as ‘Enterprise marketing technology that supports customer data management, analytics, segmentation, and workflow tools for designing, executing, and measuring marketing engagement across digital and offline channels.’ The overview recognises that B2C marketers are shifting their CCMH investments from traditional campaigns to investing more in providing customers with personalized and meaningful interactions. Marketers can use Cross-Channel Marketing Hubs, according to Forrester,